

Home > News > 2022

> U.S. FDA Clears Terumo Blood and Cell Technologies' New Plasma Collection Technology

U.S. FDA Clears Terumo Blood and Cell Technologies' New Plasma Collection Technology

The Rika Plasma Donation System is designed to optimize plasma collection to help patients affected by life-threatening illnesses

March 10, 2022

- The Rika Plasma Donation System (Rika) is designed for donor comfort and safety. On average, it completes plasma collections in 35 minutes or less, ensures there is never more than 200 milliliters of blood outside the donor's body at one time and has an advanced control system to guide device operators.
- Rika will debut in CSL Plasma centers in the United States. CSL Plasma is a subsidiary of global biotherapeutics company CSL Behring, which manufactures lifesaving plasma-derived therapies for people in more than 100 countries.
- It can take 130 plasma donations to treat the annual needs of just one patient with a primary immune deficiency, according to the [Plasma Protein Therapeutics Association](#).

LAKEWOOD, Colo., U.S.A., 10 March 2022 - Today, the U.S. Food and Drug Administration (FDA) cleared the new plasma collection system developed by [Terumo Blood and Cell Technologies](#) (Terumo BCT), a medical technology company. Rika is a next-generation automated technology focused on the experience of plasma center employees and donors. It includes safety features to minimize operator errors and collects plasma in 35 minutes or less. Rika will debut this spring in a

limited market release at CSL Plasma collection centers in the Denver, Colorado area. Plans are underway for rollout at additional CSL Plasma centers in 2022.

Rika was developed in response to the industry's need for technological advancement and process improvements to drive efficiency and quality while maintaining donor safety and a sufficient plasma supply.

Investing in the source plasma industry is a natural evolution in the Terumo Blood and Cell Technologies portfolio given its experience and leadership in apheresis technology. The company spends three times more than the industry average in development as an innovation partner to customers globally.

"Rika will revolutionize plasma collection center operations," said Antoinette Gawin, President and Chief Executive Officer, Terumo Blood and Cell Technologies. "We innovated around the donor and plasma center experience, creating an entire new ecosystem. At the heart of our innovation is operational efficiency designed to collect plasma in 35 minutes or less. This will help meet the need for plasma-derived therapies. Today, as an example, it could take 130 donations to treat one patient with a primary immunodeficiency for a year. This is such an important moment for us to Contribute to Society through Healthcare and fulfill our purpose of reaching more patients."

The new technology is focused on donor and plasma collection center employee experience. A collection time of 35 minutes or less, combined with volume of 200 milliliters or less outside the donor's body, can mean a more comfortable donation experience. Rika's advanced control system enhances donor safety by monitoring the process and providing alerts and visual cues that guide the operator. Rika makes automatic adjustments during each procedure, enabling a more seamless operator experience and the ability to spend more time with the donor.

Rika is part of an extensive ecosystem that integrates plasma collection technology, IT solutions, services and program support. All this is anticipated to support center productivity and efficiency to optimize plasma collections and meet the needs of patients who rely on plasma-derived therapies.

"With this crucial milestone achieved, we look forward to rolling this new technology out to our U.S. collection centers," said CSL Plasma General Manager Michelle Meyer. "CSL Plasma's decision to work with Terumo Blood and Cell Technologies is consistent with our business goals

to improve the donor and employee experience through innovation and remain the plasma donation center of choice."

Photo: Rika is a next-generation automated technology focused on the experience of plasma center employees and donors. It includes safety features to minimize operator errors and collects plasma in 35 minutes or less.



About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and

cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colo., U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

About Terumo

Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of "Contributing to Society through Healthcare." Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.

Media Contact

Corporate Communication Dept., Terumo Corporation

Contact us [➤](#)

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.

Copyright © 2025 Terumo Corporation, All Rights Reserved.